Pharmacy Times July 6, 2024
Mike Munsell, PhD

Real-world data and artificial intelligence (AI) are poised to revolutionize drug development by optimizing clinical trials and regulatory approvals, if data quality and patient privacy challenges are addressed.

Earlier this month, Dandelion Health announced the launch of the first artificial intelligence (AI) database specifically aimed at bolstering research for GLP-1 drugs, giving trial sponsors unprecedented insights into which indications to investigate next.1 The announcement from Dandelion is the latest example of a growing desire in health care analytics to use AI and machine learning (ML)–driven analysis of real-world data (RWD) to find new indications for approved drugs.

Beyond research and development for new indications and molecule structures, AI technology could be revolutionary for clinical trials, helping vastly reduce the cost...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Big Data, Clinical Trials, Technology, Trends
Future Trends for Clinical Trials in 2025 and Beyond
The Future of Clinical Trials: Four Key Trends to Watch in 2025
Small cell lung cancer: Navigating the global clinical trial landscape
Generative AI has ‘potential to revolutionise clinical development’
Treating Covid burnout with ’shrooms

Share This Article